Blood donor derived dendritic cells and cytotoxic T cells for specific fusion‐gene adoptive immunotherapy
Identifieur interne : 002C71 ( Main/Exploration ); précédent : 002C70; suivant : 002C72Blood donor derived dendritic cells and cytotoxic T cells for specific fusion‐gene adoptive immunotherapy
Auteurs : R. C. J. Gallagher [Royaume-Uni] ; M. Waterfall ; K. Samuel [Royaume-Uni] ; M. L. Turner [Royaume-Uni]Source :
- Vox Sanguinis [ 0042-9007 ] ; 2007-05.
English descriptors
- Teeft :
- Acute myeloid leukaemia, Acute promyelocytic leukaemia, Acute promyelocytic leukemia, Acute promyelocytic leukemia cells, Adoptive immunotherapy, Amino acids, Assay, Blackwell publishing, Blood donations, Blood donors, Cancer immunotherapy, Cdna, Cell line, Cell surface markers, Clinical trials, Coding sequence, Control plasmid, Control plasmid encoding lacz, Crpmi, Cytometric analysis, Cytotoxic, Dendritic, Dendritic cell, Dendritic cells, Donation, Donor, Effector cells, Elispot, Elispot assay, Elispot reader, Expression vector, Fusion point, Fusion protein, Gallagher, Granzyme, High band, Immune, Immune response, Immune system, Immunol, Immunotherapy, Incomplete rpmi, Individual donors, Individual patients, Internal methionine codon, Journal compilation, Kozak consensus sequence, Leukaemia, Leukaemic, Leukaemic cell line, Leukemia, Lymphocyte, Methionine, Middle band, Mutation, Novel antigens, Novel peptide, Pbmc, Peptide, Peripheral blood, Plasmid, Proc natl acad, Promyelocytic, Regenerative medicine, Retinoic, Retinoic acid, Retinoic acid receptor, Sanguinis, Separate transfections, Spontaneous release, Stimulatory sequence, Strongest correlations, Suitable donors, Supplementary material, Target cells, Tissue culture, Transfected, Transfection, Translation reaction, Treatment option, Triplicate wells, Tumor cells.
Abstract
Background and Objectives Therapeutic immunological reagents tailored to individual patients have been shown to be a viable treatment strategy for some forms of leukaemia. This work investigates the possibility of using blood donations as a source of leukaemia‐specific immune therapeutics. Materials and Methods The acute promyelocytic cell line NB4 carrying the PML‐RARα fusion was used as a target for cytotoxic T lymphocytes (CTL) stimulated to recognize the fusion. Stimulation of CTL was by production of dendritic cells pulsed with plasmid vectors containing polymerase chain reaction (PCR)‐generated sequences of PML‐RARα derived from NB4 cells. PCR primer design included a Kozak consensus sequence to allow correct translation of the nucleic acid into protein. Identification of specific cytotoxicity was by both Granzyme B ELISPOT and by 51Cr‐release assays. Results Specific CTL activity targeting NB4 cells can be generated from donor‐derived peripheral blood mononuclear cells. However, individual donors appear to respond differently to the length of stimulatory sequence encoded in the vector. Use of an internal methionine in the PML gene, which also satisfies the Kozak rules, allows translation in vitro and, thus, might provide a suitable start site for stimulation using acute promyelocytic leukaemia‐specific sequence. Conclusion The work presented here suggests that blood donor derived dendritic cells can be used to stimulate leukaemia‐specific CTL from the same donation ex vivo. This would enable the generation of patient‐specific therapeutics from major histocompatibility (MHC)‐matched allogeneic donors. However, different MHC‐matched donors might vary in their response depending on the length of the antigenic sequence.
Url:
DOI: 10.1111/j.1423-0410.2006.00873.x
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 001B73
- to stream Istex, to step Curation: 001B73
- to stream Istex, to step Checkpoint: 000924
- to stream Main, to step Merge: 002C97
- to stream Main, to step Curation: 002C71
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Blood donor derived dendritic cells and cytotoxic T cells for specific fusion‐gene adoptive immunotherapy</title><author><name sortKey="Gallagher, R C J" sort="Gallagher, R C J" uniqKey="Gallagher R" first="R. C. J." last="Gallagher">R. C. J. Gallagher</name></author><author><name sortKey="Waterfall, M" sort="Waterfall, M" uniqKey="Waterfall M" first="M." last="Waterfall">M. Waterfall</name></author><author><name sortKey="Samuel, K" sort="Samuel, K" uniqKey="Samuel K" first="K." last="Samuel">K. Samuel</name></author><author><name sortKey="Turner, M L" sort="Turner, M L" uniqKey="Turner M" first="M. L." last="Turner">M. L. Turner</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:D524E949D5F0319FC68F57B1330033810F4E7079</idno><date when="2007" year="2007">2007</date><idno type="doi">10.1111/j.1423-0410.2006.00873.x</idno><idno type="url">https://api.istex.fr/ark:/67375/WNG-WJQQ65Q0-R/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">001B73</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">001B73</idno><idno type="wicri:Area/Istex/Curation">001B73</idno><idno type="wicri:Area/Istex/Checkpoint">000924</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000924</idno><idno type="wicri:doubleKey">0042-9007:2007:Gallagher R:blood:donor:derived</idno><idno type="wicri:Area/Main/Merge">002C97</idno><idno type="wicri:Area/Main/Curation">002C71</idno><idno type="wicri:Area/Main/Exploration">002C71</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main">Blood donor derived dendritic cells and cytotoxic T cells for specific fusion‐gene adoptive immunotherapy</title><author><name sortKey="Gallagher, R C J" sort="Gallagher, R C J" uniqKey="Gallagher R" first="R. C. J." last="Gallagher">R. C. J. Gallagher</name><affiliation wicri:level="3"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>SNBTS Cell Therapy Group, Centre for Regenerative Medicine, Edinburgh</wicri:regionArea><placeName><settlement type="city">Édimbourg</settlement><region type="country">Écosse</region></placeName></affiliation></author><author><name sortKey="Waterfall, M" sort="Waterfall, M" uniqKey="Waterfall M" first="M." last="Waterfall">M. Waterfall</name></author><author><name sortKey="Samuel, K" sort="Samuel, K" uniqKey="Samuel K" first="K." last="Samuel">K. Samuel</name><affiliation wicri:level="3"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>SNBTS Cell Therapy Group, Centre for Regenerative Medicine, Edinburgh</wicri:regionArea><placeName><settlement type="city">Édimbourg</settlement><region type="country">Écosse</region></placeName></affiliation></author><author><name sortKey="Turner, M L" sort="Turner, M L" uniqKey="Turner M" first="M. L." last="Turner">M. L. Turner</name><affiliation wicri:level="3"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>SNBTS Cell Therapy Group, Centre for Regenerative Medicine, Edinburgh</wicri:regionArea><placeName><settlement type="city">Édimbourg</settlement><region type="country">Écosse</region></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j" type="main">Vox Sanguinis</title><title level="j" type="alt">VOX SANGUINIS</title><idno type="ISSN">0042-9007</idno><idno type="eISSN">1423-0410</idno><imprint><biblScope unit="vol">92</biblScope><biblScope unit="issue">4</biblScope><biblScope unit="page" from="351">351</biblScope><biblScope unit="page" to="360">360</biblScope><biblScope unit="page-count">10</biblScope><publisher>Blackwell Publishing Ltd</publisher><pubPlace>Oxford, UK</pubPlace><date type="published" when="2007-05">2007-05</date></imprint><idno type="ISSN">0042-9007</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0042-9007</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="Teeft" xml:lang="en"><term>Acute myeloid leukaemia</term><term>Acute promyelocytic leukaemia</term><term>Acute promyelocytic leukemia</term><term>Acute promyelocytic leukemia cells</term><term>Adoptive immunotherapy</term><term>Amino acids</term><term>Assay</term><term>Blackwell publishing</term><term>Blood donations</term><term>Blood donors</term><term>Cancer immunotherapy</term><term>Cdna</term><term>Cell line</term><term>Cell surface markers</term><term>Clinical trials</term><term>Coding sequence</term><term>Control plasmid</term><term>Control plasmid encoding lacz</term><term>Crpmi</term><term>Cytometric analysis</term><term>Cytotoxic</term><term>Dendritic</term><term>Dendritic cell</term><term>Dendritic cells</term><term>Donation</term><term>Donor</term><term>Effector cells</term><term>Elispot</term><term>Elispot assay</term><term>Elispot reader</term><term>Expression vector</term><term>Fusion point</term><term>Fusion protein</term><term>Gallagher</term><term>Granzyme</term><term>High band</term><term>Immune</term><term>Immune response</term><term>Immune system</term><term>Immunol</term><term>Immunotherapy</term><term>Incomplete rpmi</term><term>Individual donors</term><term>Individual patients</term><term>Internal methionine codon</term><term>Journal compilation</term><term>Kozak consensus sequence</term><term>Leukaemia</term><term>Leukaemic</term><term>Leukaemic cell line</term><term>Leukemia</term><term>Lymphocyte</term><term>Methionine</term><term>Middle band</term><term>Mutation</term><term>Novel antigens</term><term>Novel peptide</term><term>Pbmc</term><term>Peptide</term><term>Peripheral blood</term><term>Plasmid</term><term>Proc natl acad</term><term>Promyelocytic</term><term>Regenerative medicine</term><term>Retinoic</term><term>Retinoic acid</term><term>Retinoic acid receptor</term><term>Sanguinis</term><term>Separate transfections</term><term>Spontaneous release</term><term>Stimulatory sequence</term><term>Strongest correlations</term><term>Suitable donors</term><term>Supplementary material</term><term>Target cells</term><term>Tissue culture</term><term>Transfected</term><term>Transfection</term><term>Translation reaction</term><term>Treatment option</term><term>Triplicate wells</term><term>Tumor cells</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Background and Objectives Therapeutic immunological reagents tailored to individual patients have been shown to be a viable treatment strategy for some forms of leukaemia. This work investigates the possibility of using blood donations as a source of leukaemia‐specific immune therapeutics. Materials and Methods The acute promyelocytic cell line NB4 carrying the PML‐RARα fusion was used as a target for cytotoxic T lymphocytes (CTL) stimulated to recognize the fusion. Stimulation of CTL was by production of dendritic cells pulsed with plasmid vectors containing polymerase chain reaction (PCR)‐generated sequences of PML‐RARα derived from NB4 cells. PCR primer design included a Kozak consensus sequence to allow correct translation of the nucleic acid into protein. Identification of specific cytotoxicity was by both Granzyme B ELISPOT and by 51Cr‐release assays. Results Specific CTL activity targeting NB4 cells can be generated from donor‐derived peripheral blood mononuclear cells. However, individual donors appear to respond differently to the length of stimulatory sequence encoded in the vector. Use of an internal methionine in the PML gene, which also satisfies the Kozak rules, allows translation in vitro and, thus, might provide a suitable start site for stimulation using acute promyelocytic leukaemia‐specific sequence. Conclusion The work presented here suggests that blood donor derived dendritic cells can be used to stimulate leukaemia‐specific CTL from the same donation ex vivo. This would enable the generation of patient‐specific therapeutics from major histocompatibility (MHC)‐matched allogeneic donors. However, different MHC‐matched donors might vary in their response depending on the length of the antigenic sequence.</div></front></TEI><affiliations><list><country><li>Royaume-Uni</li></country><region><li>Écosse</li></region><settlement><li>Édimbourg</li></settlement></list><tree><noCountry><name sortKey="Waterfall, M" sort="Waterfall, M" uniqKey="Waterfall M" first="M." last="Waterfall">M. Waterfall</name></noCountry><country name="Royaume-Uni"><region name="Écosse"><name sortKey="Gallagher, R C J" sort="Gallagher, R C J" uniqKey="Gallagher R" first="R. C. J." last="Gallagher">R. C. J. Gallagher</name></region><name sortKey="Samuel, K" sort="Samuel, K" uniqKey="Samuel K" first="K." last="Samuel">K. Samuel</name><name sortKey="Turner, M L" sort="Turner, M L" uniqKey="Turner M" first="M. L." last="Turner">M. L. Turner</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/MersV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002C71 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002C71 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= MersV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:D524E949D5F0319FC68F57B1330033810F4E7079
|texte= Blood donor derived dendritic cells and cytotoxic T cells for specific fusion‐gene adoptive immunotherapy
}}
| This area was generated with Dilib version V0.6.33. |  |